AMRN
Amarin Corporation plc
AMRN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMRN overall, supported by stronger fundamentals and stronger modeled upside.
AMRN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Unavailable |
AMRN's cash flow is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMRN PE Valuation
AMRN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Weakening | |
| Limited | |
| High |
Analysts expect AMRN's losses to grow, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AMRN on the outlook, with more favorable earnings and revenue expectations.
AMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$3.20 |
| Q2 2026 | -$0.07 | +$4.36 |
| Q1 2026 | -$0.08 | +$4.32 |
| Q4 2025 | -$0.85 | +$3.15 |
| Q3 2025 | -$3.25 | -$1.25 |
| Q2 2025 | -$4.43 | -$2.63 |
| Q1 2025 | -$4.40 | -$1.80 |
| Q4 2024 | -$4.00 | -$1.00 |
AMRN is still losing money, but far less than before: $0.05 per share over the past year, against $5.36 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AMRN on earnings quality, reporting a profit while its opponent remains loss making.
AMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $39.6M | -20% |
| Q2 2026 | $42.2M | -42% |
| Q1 2026 | $45.1M | +7.4% |
| Q4 2025 | $49.2M | -21% |
| Q3 2025 | $49.7M | +17% |
| Q2 2025 | $72.7M | +7.8% |
| Q1 2025 | $42M | -26% |
| Q4 2024 | $62.3M | -17% |
AMRN's revenue has slid since its 2020 peak: $40M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6% | +16 points |
| Q2 2026 | -28% | -6.5 points |
| Q1 2026 | -25% | +15 points |
| Q4 2025 | -13% | +72 points |
| Q3 2025 | -22% | +37 points |
| Q2 2025 | -22% | -21 points |
| Q1 2025 | -40% | -16 points |
| Q4 2024 | -84% | -78 points |
AMRN's operating margin was −6% last quarter, up 16 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AMRN on profitability, with a higher operating margin.
AMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | +$21.9M |
| Q2 2026 | $6.6M | -60% |
| Q1 2026 | $6.4M | +$18.8M |
| Q4 2025 | $15.3M | +$28.6M |
| Q3 2025 | -$12.7M | -$10.3M |
| Q2 2025 | $16.6M | +$19.4M |
| Q1 2025 | -$12.5M | +$142K |
| Q4 2024 | -$13.3M | -$12.7M |
AMRN's free cash flow has turned positive after two years mostly in the red: $37M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMRN on cash flow, with more consistent year-over-year improvement.
AMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +11.4M shares |
| 1 year | +3% | +12.3M shares |
| 3 years | +1995% | +407M shares |
| 5 years | +2058% | +408M shares |
| Available history | +2398% | +411M shares |
AMRN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMRN Net Leverage
AMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 13.7 | Oversold |
AMRN's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMRN PE vs Healthcare Sector
AMRN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 2.8% below |
| 20 week MA | $13.3 | 12% below |
| 50 week MA | $14.2 | 18% below |
| 100 week MA | $13.7 | 15% below |
| 200 week MA | $16.8 | 31% below |
AMRN is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMRN on trend strength, trading above more of its moving averages.
AMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $431.0 | $100.2 | -77% |
| 2021 | $100.2 | $70.2 | -30% |
| 2022 | $70.2 | $25.0 | -64% |
| 2023 | $25.0 | $17.4 | -30% |
| 2024 | $17.4 | $8.96 | -49% |
| 2025 | $8.96 | $14.1 | +58% |
| 2026 YTD | $14.1 | $11.7 | -17% |
AMRN has finished lower in five of the last six years. It's down 17% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMRN on returns for 2026, with the stronger performance.